ONO PHARMACEUTICAL CO., LTD. Logo

ONO PHARMACEUTICAL CO., LTD.

Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.

4528 | T

Overview

Corporate Details

ISIN(s):
JP3197600004
LEI:
Country:
Japan
Address:
大阪市中央区道修町二丁目1番5号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ONO PHARMACEUTICAL CO., LTD., established in 1717, is a research and development-oriented pharmaceutical company dedicated to discovering and delivering innovative medicines. With a legacy spanning over three centuries, the company focuses on addressing high unmet medical needs through the creation, manufacturing, and sale of prescription drugs. Its primary therapeutic areas include oncology, immunology, neurology, and other specialty fields, with a portfolio of treatments for conditions such as cancer and type II diabetes. The company is committed to a mission of fighting disease and pain by providing new therapeutic options to patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 01:00
Registration Form
確認書
Japanese 9.1 KB
2025-11-06 01:00
Interim Report
半期報告書-第78期(2025/04/01-2026/03/31)
Japanese 328.6 KB
2025-07-01 09:06
Registration Form
確認書
Japanese 9.2 KB
2025-07-01 09:00
Annual Report
訂正有価証券報告書-第77期(2024/04/01-2025/03/31)
Japanese 1.3 MB
2025-06-20 02:00
Post-Annual General Meeting Information
臨時報告書
Japanese 25.3 KB
2025-06-19 09:06
Share Issue/Capital Change
臨時報告書
Japanese 39.9 KB
2025-06-19 09:05
Share Issue/Capital Change
臨時報告書
Japanese 41.7 KB
2025-06-19 09:02
Governance Information
内部統制報告書-第77期(2024/04/01-2025/03/31)
Japanese 26.0 KB
2025-06-19 09:01
Registration Form
確認書
Japanese 9.2 KB
2025-06-19 09:00
Annual Report
有価証券報告書-第77期(2024/04/01-2025/03/31)
Japanese 2.5 MB
2024-11-06 01:00
Interim Report
半期報告書-第77期(2024/04/01-2025/03/31)
Japanese 334.0 KB
2024-11-06 01:00
Interim Report
確認書
Japanese 9.1 KB
2024-06-21 02:05
Post-Annual General Meeting Information
臨時報告書
Japanese 27.2 KB
2024-06-21 02:04
Governance Information
内部統制報告書-第76期(2023/04/01-2024/03/31)
Japanese 24.4 KB
2024-06-21 02:03
Registration Form
確認書
Japanese 9.2 KB

Automate Your Workflow. Get a real-time feed of all ONO PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ONO PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ONO PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.